Hisanori Umehara
Overview
Explore the profile of Hisanori Umehara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
134
Citations
5483
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen Y, Ye C, Yang P, Zhang W, Dai L, Wei W, et al.
Ann Rheum Dis
. 2025 Feb;
PMID: 39956699
Objectives: To investigate the effects of thalidomide in preventing disease relapse with 'zero' glucocorticoids (GCs) usage in IgG4-related disease (IgG4-RD). Methods: This was a multicentre, randomised, double-blinded, placebo-controlled study, in...
2.
Ming B, Li L, Cai S, Hu Z, Gao R, Umehara H, et al.
J Leukoc Biol
. 2025 Feb;
117(2).
PMID: 39953919
Sjogren's syndrome (SS) is an autoimmune epithelitis characterized by focal lymphocytic infiltration against self-antigens leading to progressive glandular dysfunction, which can develop to multisystem manifestation. The classification criteria for SS...
3.
Yamamoto M, Kanda M, Mizushima I, Kanno A, Umemura T, Ikeura T, et al.
Immunol Med
. 2024 Nov;
:1-11.
PMID: 39607031
We started a registry for cases of immunoglobulin (Ig)G4-related disease (IgG4-RD) in December 2019 to clarify the clinical profile of IgG4-RD. In this study, clinical information from 854 cases registered...
4.
Stone J, Khosroshahi A, Zhang W, Della Torre E, Okazaki K, Tanaka Y, et al.
N Engl J Med
. 2024 Nov;
PMID: 39541094
Background: IgG4-related disease is a multiorgan, relapsing, fibroinflammatory, immune-mediated disorder with no approved therapy. Inebilizumab targets and depletes CD19+ B cells and may be effective for treating patients with IgG4-related...
5.
Kanda M, Nagahata K, Moriyama M, Takano K, Kamekura R, Yoshifuji H, et al.
Mod Rheumatol
. 2024 Oct;
PMID: 39441008
Objectives: For the diagnosis of IgG4-related dacryoadenitis and sialadenitis, either revised comprehensive diagnostic criteria or organ-specific diagnostic criteria for IgG4-related dacryoadenitis and sialadenitis in 2008 were applied; however, the collected...
6.
Jiang P, Jing Y, Zhao S, Lan C, Yang L, Dai X, et al.
Nat Commun
. 2024 Mar;
15(1):2627.
PMID: 38521787
IgG4-related disease (IgG4-RD) has complex clinical manifestations ranging from fibrosis and inflammation to deregulated metabolism. The molecular mechanisms underpinning these phenotypes are unclear. In this study, by using IgG4-RD patient...
7.
Terao C, Ota M, Iwasaki T, Shiokawa M, Kawaguchi S, Kuriyama K, et al.
Lancet Rheumatol
. 2024 Jan;
1(1):e14-e22.
PMID: 38229354
Background: IgG4-related disease is a newly recognised immunopathological entity that includes autoimmune pancreatitis, IgG4-related sialadenitis, and IgG4-related kidney disease. To understand the genetic landscape of IgG4-related disease, we did a...
8.
Tanaka Y, Takeuchi T, Yamanaka H, Nanki T, Umehara H, Yasuda N, et al.
Mod Rheumatol
. 2023 Jan;
34(1):37-44.
PMID: 36680426
Objectives: To evaluate the long-term safety and efficacy of E6011, a humanized anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis (RA) with an inadequate response to methotrexate (MTX). Methods: Active...
9.
Tanaka Y, Takeuchi T, Yamanaka H, Nanki T, Umehara H, Yasuda N, et al.
Mod Rheumatol
. 2023 Jan;
34(1):45-49.
PMID: 36680420
Objectives: The objective of the study is to evaluate the long-term safety and efficacy of E6011, a humanized anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis with an inadequate response...
10.
Yoshifuji H, Umehara H
Mod Rheumatol
. 2022 Aug;
33(2):252-257.
PMID: 35993488
Immunoglobulin G4-related disease (IgG4-RD) is a chronic fibro-inflammatory disease that may cause dysfunction in various organs. Worldwide multidisciplinary experts attending the Fourth International Symposium on IgG4-Related Disease in Japan in...